SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is moving its lead therapeutic candidate, GEP-44, closer to clinical trials by initiating a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program. The studies, to be conducted with LabCorp, are designed to assess safety, dosing parameters and biomarkers across multiple species, supporting future Phase I clinical trials for the GLP-1 agonist peptide targeting Type II diabetes and obesity.
The company also outlined expanded investor outreach initiatives, including a strategic agreement with Investor Brand Network (IBN) to leverage its syndication network of more than 5,000 media outlets. Additional marketing engagements and early-stage discussions to potentially acquire or license intellectual property related to ibogaine-based therapies are also underway. SureNano said these efforts are intended to strengthen market awareness while supporting continued advancement of its therapeutic pipeline.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. The company has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery (refer to press release dated February 23, 2026).
The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano™ surfactant, a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The company has an exclusive license to distribute the SureNano™ surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.
For more information, visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
